Four paraoxonase gene polymorphisms in 11 212 cases of coronary heart disease and 12 786 controls: meta-analysis of 43 studies

Jeremy G. Wheeler(University of Cambridge), John Danesh(University of California, Los Angeles), Hugh Watkins(John Radcliffe Hospital), Bernard Keavney(Manchester Academic Health Science Centre), Rory Collins(University of Oxford)

The Lancet

February 1, 2004

10.1016/s0140-6736(04)15642-0

Cited by 320

Related Papers

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents

|The Lancet|2016|2.8k

Interpretation of the evidence for the efficacy and safety of statin therapy

|The Lancet|2016|1.8k

Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies

|International Journal of Epidemiology|2019|1.4k